Ankylosing spondylitis causes high burden to patients and the healthcare system: results from a German claims database analysis
Ankylosing spondylitis causes high burden to patients and the healthcare system: results from a German claims database analysis
复制标题
DOI：
10.1007/s00296-018-4124-z
复制
发表时间：
2018-11-01
影响因子：
4
通讯作者：
Braun, Sebastian
中科院分区：
文献类型：
--
作者：
Krueger, Klaus;von Hinueber, Ulrich;Braun, Sebastian
为了比较强直性脊柱炎（AS）患者与德国国家健康保险（SHI）系统未覆盖AS的一般人群的匹配样本之间的医疗资源利用和成本，使用匿名SHI索赔数据进行了非干预性回顾性匹配队列分析。分析了2011年1月1日至2014年12月31日的数据。在包括2013年全年的入组期间编码诊断为AS的个体与整个研究期间未诊断为AS的个体按年龄、性别、住院和合并症直接匹配（1：5）。分析了2013年全因医疗资源利用率和直接成本。应用统计检验比较两个抽样群体之间的差异。2013年，10，208名AS患者被确定并与来自普通人群的51，040名无AS患者的样本相匹配。在AS队列中，所有医疗保健部门（住院、门诊、药品、补救措施、设备和辅助设备以及病假）的医疗资源利用率均显著较高。与一般人群相比，AS队列中每例患者的平均全因医疗费用高出约2475欧元。最重要的成本驱动因素是住院和药物，10%的患者使用bDMARD。来自德国索赔数据库分析的真实数据显示，AS与医疗保健系统的经济负担大幅增加有关。
To compare healthcare resource utilization and costs between ankylosing spondylitis (AS) patients and a matched sample from the general population without AS covered by the German Statutory Health Insurance (SHI) system, a non-interventional retrospectively matched cohort analysis was conducted using anonymized SHI claims data. Data from January 1st, 2011 through December 31st, 2014 were analyzed. Individuals with a coded diagnosis of AS during the enrollment period comprising the full year of 2013 were directly matched (1:5) to individuals without AS diagnosis in the whole study period by age, gender, hospitalizations, and comorbidities. All-cause healthcare resource utilization and direct costs were analyzed for the year 2013. Statistical tests were applied to compare the differences between the two sampled populations. In 2013, 10,208 AS patients were identified and matched to a sample of 51,040 patients without AS from the general population. Healthcare resource utilization was significantly higher in all healthcare sectors (inpatient, outpatient, pharmaceuticals, remedies, devices and aids, and sick leave) in the AS cohort. Mean all-cause healthcare costs per patient were about Euro2475 higher in the AS cohort compared to the general population. Most important cost drivers were hospitalizations and pharmaceuticals in terms of bDMARDs prescribed in 10% of the patients. Real-world data from this German claims database analysis showed that AS is associated with a substantial incremental economic burden to the healthcare system.